Form 8-K ZS Pharma, Inc. For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
JPMorgan Downgrades ZS Pharma (ZSPH) to Neutral
November 9, 2015 7:17 AM ESTJPMorgan downgraded ZS Pharma (NASDAQ: ZSPH) from Overweight to Neutral with a price target of $90.00 (from $75.00).
For an analyst ratings summary and ratings history on ZS Pharma click here. For more ratings news on ZS Pharma click here.
Shares of ZS Pharma closed at $89.04 yesterday.
... MoreAstraZeneca (AZN) to Acquire ZS Pharma (ZSPH) in $2.7B Deal
November 6, 2015 6:36 AM ESTAstraZeneca (NYSE: AZN) announced today that it has entered into a definitive agreement to acquire ZS Pharma (NASDAQ: ZSPH), a biopharmaceutical company based in San Mateo, California. ZS Pharma uses its proprietary ionÂ-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF).
The transaction will give AstraZeneca access to the potassium-binding compound ZS-9, a potential best-in-class treatment for hyperkalaemia, a condition... More
